GSK, Valeant Submit NDA for Epilepsy Drug

November 11, 2009
GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International have filed an NDA for their epilepsy treatment retigabine with the FDA and a marketing authorization application with the European Medicines Agency. Retigabine is intended as an adjunctive therapy to treat adult epilepsy patients with partial-onset seizures, the companies say in a statement last week.
Washington Drug Letter